Moving and improving for Omicron

Published: 31-Mar-2010
Manufacturing Finance

Omicron Research Limited, the UK distributor for CAMAG and Distek Inc., is excited to announce that it will be based in new premises from April 2010.

Omicron Research Limited, the UK distributor for CAMAG and Distek Inc., is excited to announce that it will be based in new premises from April 2010.

Located in Hungerford, Berkshire, the modern, fully redecorated building will house the office, warehouse and workshop departments of our scientific equipment distribution and support business. For the first time, Omicron’s complete operation will be housed under one roof, providing a more responsive and streamlined service to customers.

A substantial investment has been made into the refurbishment of the new premises and the upgrade of technology, ensuring continuation of the high level of customer service for which Omicron is renowned. With immediate access to the M4, the new location offers staff and clientele a more convenient and professional environment in which to do business.

To coincide with the move the company hase enhanced its website by adding two new functionalities. An extensive parts catalogue is now available on-line, complemented by a new quotation request facility, providing a fast, easy to use service for customers. We invite you to visit and explore our website, www.omicron-uk.com, where you will find information on an extensive range of dissolution, chromatography, spectroscopy, OPLC and capillary electrophoresis products.
See more

You may also like

Manufacturing

HPTLC – a thoroughly modern method

Read more
High Performance Thin Layer Chromatography (HPTLC) is firmly established as a fast and effective analytical tool, yet in many laboratories traditional TLC is still the norm.

Trending Articles

  1. Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
  2. Strengthening US pharmaceutical supply: SCHOTT Pharma inaugurates expanded vial production in Lebanon, PA SCHOTT Pharma has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs — from biologics and other complex injectable therapies to vaccines and emergency room medications
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
  4. AI-designed drug product enters clinical development Phase I study of an AI-designed oral formulation sets a new standard in drug development

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Manufacturing

HPTLC – a thoroughly modern method

High Performance Thin Layer Chromatography (HPTLC) is firmly established as a fast and effective analytical tool, yet in many laboratories traditional TLC is still the norm.
Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Finance

UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures

Heligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines
You need to be a subscriber to read this article.
Click here to find out more.
Finance

ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum

From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Subscribe now